Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: SDZNY )

41.87 +0.40 (+0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about SDZNY

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing... 
Via Benzinga
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC. 
Via Benzinga
Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines
Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines 
Via News Direct
Exposures Product Safety
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
3 Spinoff Stocks You Should Buy Now: July 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early. 
Via InvestorPlace
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchasers without admitting wrongdoing. Post-approval, litigation continues with... 
Via Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs. 
Via Benzinga
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC:  
Via Benzinga
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
Novartis AG (NYSE: NVS) reported  
Via Benzinga
Topics Earnings
Exposures Financial
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.